scholarly journals Evaluation of Plasma Circulating Cell Free DNA Concentration and Integrity in Patients with Prostate Cancer in Jamaica: A Preliminary Study

Diseases ◽  
2020 ◽  
Vol 8 (3) ◽  
pp. 34
Author(s):  
Andrew Condappa ◽  
Donovan McGrowder ◽  
William Aiken ◽  
Wayne McLaughlin ◽  
Maxine Gossell-Williams
Keyword(s):  
Prostate Cancer ◽  
Gleason Score ◽  
Quantitative Polymerase Chain Reaction ◽  
Specific Antigen ◽  
Total Prostate Specific Antigen ◽  
Noninvasive Biomarker ◽  
Preliminary Study ◽  
Polymerase Chain ◽  
Free Circulating Dna ◽  
Total Psa

Background: Cell free circulating DNA (cfcDNA) is a promising diagnostic tool for prostate cancer (PCa). This study aimed to measure the cfcDNA concentration and integrity in PCa patients using quantitative polymerase chain reaction (qPCR) analysis. This study also assessed the correlation between these molecular biomarkers with total prostate-specific antigen (PSA), Gleason score, prostate volume, and age. Methods: Eleven PCa patients and 9 persons with benign prostatic hyperplasia (BPH) were recruited. Blood samples were collected before prostate biopsy and plasma quantified by qPCR amplification of the ALU 115 DNA sequence, with the ratio of ALU 247 to ALU 115 reflecting cfcDNA integrity. Results: There were no significant differences in median, interquartile range (IQR) cfcDNA concentration or cfcDNA integrity between the patients with PCa (47.9 (214.93) ng/mL; 0.61 (0.49)) and persons with BPH (41.5 (55.13) ng/mL, p = 0.382; 0.67 (0.45), p = 0.342). A weakly positive correlation exists between cfcDNA concentration and total PSA (r = 0.200, p = 0.555) but not with age or Gleason score in PCa patients. Conclusion: cfcDNA concentration was relatively nonsignificantly higher in PCa patients in comparison to persons with BPH, whereas cfcDNA integrity was similar in both groups. Though limited in sample size, this study shows that cfcDNA concentration may be a potentially valuable noninvasive biomarker for the diagnosis of PCa.

On the Clinical Usefulness of the Free-to-Total Prostate-Specific Antigen Ratio

2006 ◽  
Vol 21 (1) ◽  
pp. 1-5 ◽  
Author(s):  
S. Ciatto ◽  
T. Rubeca ◽  
R. Franceschini ◽  
C. Trevisiol ◽  
M. Confortini ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Clinical Usefulness ◽  
Clinical Use ◽  
Prostate Biopsies ◽  
Total Prostate Specific Antigen ◽  
Total Psa

The free-to-total prostate-specific antigen ratio (F/T PSA) is associated with the presence of prostate cancer and is thus used as an indicator for suspicion of prostate cancer and as a determinant for biopsy. We reviewed a recent retrospective series of 966 consecutive prostate biopsies where F/T PSA was blindly determined and did not influence biopsy indication. We simulated the association of F/T PSA with biopsy outcome and its impact as a biopsy determinant. When adopting an F/T PSA cutoff of 10%, 13%, 16% or 20% among random sextant biopsies in the 4–10 ng/mL total PSA range, the sensitivity was 15%, 37%, 55% and 72% and the specificity 89%, 80%, 64% and 44%, respectively. Using F/T PSA as a biopsy determinant, from 1.7 to 2.6 cancer biopsies would have been delayed to avoid 10 benign biopsies. As this balance is not acceptable, F/T PSA has no role as a biopsy indicator and its clinical use is questionable.

scholarly journals AGE, TOTAL PSA, PSA DENSITY AND GLEASON SCORE, TAUS AS PREDICTIVE FACTORS IN PATIENTS WITH PROSTATE CANCER

2016 ◽  
Vol 23 (1) ◽  
Author(s):  
Daruqutni Albar ◽  
Sungsang Rochadi
Keyword(s):  
Prostate Cancer ◽  
Normal Distribution ◽  
Gleason Score ◽  
Predictive Factors ◽  
Specific Antigen ◽  
Retrospective Case ◽  
Psa Density ◽  
Abnormal Distribution ◽  
Total Psa ◽  
Spearman Test

Objective: To find the factors related as predictive factors for Gleason score in prostate cancer patients. Material & methods: This study obtained a total sample of 144 patients with prostate cancer in Sardjito General Hospital Yogyakarta in 2009-2013. Of the total 144 patients, only 64 patients had complete medical records. All patient samples were patients who had biopsy of the prostate. This study is a retrospective case-control study to predict the Gleason Score in patients with prostate cancer in terms of age, total prostate specific antigen (PSA), PSA density and TAUS. Normality test assessed the distribution of the data. Pearson test assessed normal distribution and Spearman test for normal distribution. All data were analyzed using SPSS version 18. Results: Analysis of data from 64 patients with prostate cancer with a normal distribution of the variables obtained on age and TAUS with p > 0.05 whereas abnormal distribution obtained on total PSA, PSA density with p < 0.05. Of the data on the data with a normal distribution, age and TAUS with values obtained p 0.039 and p 0.738. From these data it can be said there is a relationship between age and Gleason score where the higher the age the higher the Gleason score. TAUS of the data can be said there is no relationship between TAUS and Gleason score. Then the abnormal distribution of the data obtained with a total PSA p < 0.001 and PSA density p < 0.001. The data is obtained from the relationship between total PSA and PSA density with Gleason score. Conclusion: It was found that age, total PSA, PSA density affect the increase in Gleason score where the higher the age, total PSA and PSA density the higher the Gleason score in patients.

scholarly journals Estudio Clínico y Epidemiológico de Cáncer de Próstata en el Hospital de Especialidades José Carrasco Arteaga de Cuenca - Ecuador, 2010 - 2015

2018 ◽  
Vol 10 (2) ◽  
pp. 110-115
Author(s):  
María Paz Orellana Jara ◽  
Juana Carolina Cordero Garate ◽  
Galo Rubén Duque Proaño
Keyword(s):  
Prostate Cancer ◽  
Risk Factors ◽  
Correlation Coefficient ◽  
Gleason Score ◽  
Clinical Stage ◽  
Specific Antigen ◽  
Positive Association ◽  
Clinical Staging ◽  
The Media ◽  
Total Psa

BACKGROUND: Prostate cancer is the fifth most common neoplasms worldwide and the second in man. In Cuenca, according to the sixth epidemiology of cancer, it is the second cause of death in males. METHODS: Observational descriptive study the sample was for convenience, made up with 315 patients with positive biopsy. The established variables were: Signs and symptoms, histopathological type, total prostate specific antigen (PSA) measure, risk factors, Gleason score, differentiation grade and clinical staging. The media and median were obtained as the crossing of variables using Pearson and Spearman correlation coefficient. The software used was STATA 12 version. RESULTS: The most common symptoms were urinary frequency (56.2 %) and dysuria (36.8 %). 312 patients presented adenocarcinoma as histopathology type. The total PSA had a median of 4.4 ng/ml and a media of 34 ng/ml. The media of age was 69 years old. 141 patients presented hypertension. About the Gleason Grading system most of people were moderately differentiated (43.6 %). 67 % of cases were diagnosed during stages I and II. The Rho correlation coefficient was 0.44 between clinical stage and Gleason score; it was of 0.36 between PSA and clinical stage. CONCLUSIONS: It was found a moderately positive association between clinical stage and Gleason score. There is no minimal measure of total PSA that could assure us there is no risk of prostate cancer. More prospective studies are needed in order to find the relation between prostate cancer and risk factors.

scholarly journals Analysis of the spatial distribution and clinical features of prostate cancer in transperineal prostate biopsy

2019 ◽  
Author(s):  
Chen Jia-Jun ◽  
Zhu Zai-Sheng ◽  
Zhu Yi-Yi ◽  
Zhou Yi-Bo ◽  
Shi Hong-Qi
Keyword(s):  
Prostate Cancer ◽  
Spatial Distribution ◽  
Prostate Specific Antigen ◽  
Gleason Score ◽  
Prostate Biopsy ◽  
Specific Antigen ◽  
Peripheral Zone ◽  
Transperineal Prostate Biopsy ◽  
Total Prostate Specific Antigen ◽  
Study Results

Abstract Background Recently, most studies on the spatial distribution of the prostate cancer are based on the samples confirmed by transrectal prostate biopsy (TRBx), which could distinguish the distribution of cancer lesions between the apex, middle and basal parts of the prostate, but the distinction between lesions in the left and right sides of prostate cancer and the transitional and peripheral bands remains to be considered. Further, there has been little research on the specific proportion of cancer in prostate biopsy tissue. The current study aimed to analyze the clinical characteristics, diagnostic efficacy of relevant indicators, and reveal the spatial distribution of prostate cancer in transperineal prostate biopsy (TPBx). Methods A total of 810 patients underwent TPUS-guided 10-core prostate biopsy in our hospital from Oct. 2016-to Feb. 2019, participants' clinical data and the diagnostic yield of the cores were recorded and retrospectively analyzed as a cross-sectional study. Results Age, total prostate specific antigen (t-PSA), prostate volume (PV), prostatic inflammation, dysuria, hematuria, asymptomatic and MRI were independent factors in prostate cancer (Pca) patients compared with non-Pca patients (P<0.05). The cut-off points for age, t-PSA, free prostate specific antigen (f-PSA), PSA density (PSAD), free/total prostate specific antigen (f/t PSA) and PV were 73years old, 15.43ng/ml, 4.545ng/ml, 0.475ng/ml*cm3, 0.123 and 41.45ml, respectively. The PRPN of left peripheral zone (LPZ) prostate tumor was elevated regardless of the Gleason score. However, the PRPN of left transitional zone (LTZ) was lower than LPZ and similar to right peripheral zone (RZ), but PRCF and CFVR were significantly higher, especially in tumors with higher Gleason score (≥8). Conclusions For Chinese, the t-PSA standard and the PSAD standard in the puncture indication should be increased, while the f/t PSA standard should be reduced. At the same time, multi-factor assessment is needed to determine whether patients need a prostate biopsy or not. The spatial distribution of prostate cancer is asymmetrical, with more cancer lesion on the left than on the right. The PRPN of LPZ is relatively higher. LTZ has higher PRCF, and most of them were large lesions with high Gleason score (≥8).

scholarly journals Comparative Assessment of the Diagnostic Performance of PCA3 in Urinary Sediments and Exosomes for Prostate Cancer in Chinese Population with the Total PSA range of 4-10 ng/ml.

2020 ◽  
Author(s):  
Zhenqiang Fang ◽  
Fan He ◽  
Huan Feng ◽  
Weishen Jia ◽  
Mengjia Sun ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Roc Analysis ◽  
Specific Antigen ◽  
Diagnostic Value ◽  
Chinese Patients ◽  
Current Evidence ◽  
Urine Sediment ◽  
Total Prostate Specific Antigen ◽  
Significant Difference ◽  
Total Psa

Abstract Background: The diagnostic value of prostate cancer antigen-3 (PCA3) in urine sediment and exosome in Chinese patients with total prostate specific antigen (PSA) ranging from 4-10ng/ml.Methods: Serum and urine samples were collected from consecutive eligible patients. The PCA3 and PSA mRNA were tested by quantitative real-time PCR. Results: Overall 130 patients were involved in this study. 113 cases in urinary sediments group and 103 cases in urinary exosomes group were finally analyzed. 24 of 130 patients (18.5%), 20 of 113 patients (17.7%) and 17 of 103 patients (16.5%) were diagnosed as PCa in the three groups, respectively. The PCA3 score and PSAD of patients with positive biopsy results were significantly higher than those with negative biopsy results in both the urinary sediments and exosomes groups, but no differences between two urinary substrates groups. The ROC analysis showed the higher values of AUC of the PCA3 score in urinary sediments and exosomes than that of serum PSA (0.728 vs 0.540, P = 0.0402; 0.740 vs 0.540, P = 0.0263), but no significant difference in term of AUC of PCA3 between two urinary substrates groups (0.728 vs 0.740, P = 0.9000), as well as when compared the AUC of the PCA3 score with that of %fPSA and PSAD (P > 0.05).Conclusion: The current evidence suggests that diagnostic performances of PCA3 in urinary sediments and exosomes were not significant different, but both were superior to serum PSA in Chinese patients with PSA 4–10ng/ml.

scholarly journals The validation results for APhiGT algorithm for clarification of prostate cancer staging before treatment (first step)

2019 ◽  
Vol 15 (2) ◽  
pp. 42-52 ◽  
Author(s):  
N. S. Sergeeva ◽  
T. E. Skachkova ◽  
N. V. Marshutina ◽  
K. M. Nushko ◽  
I. M. Shevchuk ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gleason Score ◽  
Specific Antigen ◽  
Area Under The Curve ◽  
Cancer Staging ◽  
Health Index ◽  
Free Psa ◽  
Prostate Health Index ◽  
Total Psa ◽  
Prostate Health

Background. We have previously described an algorithm APhiGT (Age, Prostate Health index, Gleason score, TNM stage) for staging of prostate cancer (PC) before treatment. The algorithm was developed by logistic regression on an educational selection (ES) of 337 PC cases. The algorithm includes data about the age of patients, the levels of total prostate-specific antigen (PSA), free PSA, [-2]proPSA and the ranked data of the Gleason score (by biopsy results) and T (by TNM).Objective. Validation of APhiGT on the validation selection (VS) of 83 PC cases was carried out in this work.Materials and methods. ROC analysis was performed in ES and VS.Results and сonclusion. It is established that area under the curve (AUC), characterizing the ability to divide clinically significant subgroups of patients (Gleason score <7 vs. Gleason score ≥7, рТ2 vs. рТ3, localized indolent PC vs. localized aggressive PC) for APhiGT both in ES and VS was significantly higher than AUC for total PSA, %[-2]proPSA in free PSA and prostate health index. At the same time, in all clinical subgroups of patients AUC for VS was lower than AUC for ES, which may be due to a significantly smaller size of VS compared to ES.

scholarly journals CAN PROSTATE-SPECIFIC ANTIGEN DENSITY AND FREE / TOTAL PROSTATE-SPECIFIC ANTIGEN RATIO PREDICT CLINICALLY SIGNIFICANT PROSTATE CANCER (GLEASON ≥ 7) IN PATİENTS DIAGNOSED PROSTATE CANCER ON BIOPSY WITH A PROSTATE-SPECIFIC ANTIGEN LEVEL OF 2.5 -10 NG/ML?

2021 ◽  
Author(s):  
Fatih Bicaklioglu ◽  
Hasan Aydin ◽  
Ahmet Özgür Güçtaş ◽  
Hamit Zafer Aksoy
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Sensitivity And Specificity ◽  
Prostate Biopsy ◽  
Specific Antigen ◽  
Free Psa ◽  
Total Prostate Specific Antigen ◽  
Prostate Specific Antigen Density ◽  
Clinically Significant ◽  
Total Psa

Introduction Many men with non-clinically significant PCa (N-CSPCa) will not progress to become symptomatic within their lifetime. If we can predict clinically significant PCa (CSPCa), we can prevent patients from unnecessary biopsies, overdiagnoses, and overtreatment. The purpose of this study was to determine whether PSAD and f/t PSA can predict CSPCa (Gleason ≥ 7) in patients diagnosed with prostate cancer on biopsy with a PSA level of 2.5-10 ng/ml or not. Materials and Methods 78 patients who underwent TRUSG-guided prostate biopsy with PSA 2.5-10.0 in our clinic between March 2017 - August 2020 and whose pathology result was reported as prostate adenocarcinoma, were retrospectively evaluated. In addition to the demographic content of the patients, PSA, free PSA, prostate size (with TRUSG), rectal examination findings and prostate biopsy pathology results were recorded. Clinically significant prostate cancer was defined as a Gleason score 7. Results The mean age of the patients was 66.9 ± 8.4, PSA value was 6.9 ± 1.8, free / total PSA ratio was 18 ± 8.1%, and PSA density was 0.150 ± 0.078. The P values of PSA, free PSA, PSAD, f/t PSA, and prostate volume between CSPCa and N- CSPCa groups were 0.010, 0.780, 0.001, 0.084, and 0.030, respectively. The area under the ROC curve (AUC) of the PSAD for predicting CSPCa was 0.719 with a 95% Cl (0.604–0.835), and the standard errors were 0.062 and 0.059, respectively. When PSAD cutoff was 0.130 for predicting CSPCa, sensitivity and specificity were 75% and 63%, respectively. Conclusion PSAD can be used for predicting CSPCa, but f/t PSA can not. PSAD is not a strong stand-alone tool with its sensitivity and specificity, but we suggest that PSAD can be a part of future nomograms for predicting CSPCa and future protocols for active surveillance. Key words:prostate-specific antigen; clinically significant prostate cancer

Sign in / Sign up

Export Citation Format

Share Document